No Data
Wells Fargo Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $85
Insmed's Promising Growth: Buy Rating Backed by Strong Performance and Strategic Advancements
TD Cowen Maintains Insmed(INSM.US) With Buy Rating
TD Cowen Reaffirms Their Buy Rating on Insmed (INSM)
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Insmed Issues Preliminary Revenue Results, Guidance for Arikayce